Business
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing
About this update from Anaptysbio, Inc.
[{"type":"text","content":"Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing imsidolimab ACORN Phase 2 trial in moderate-to-severe acne in H1 2022 and HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa in H2 2022Rosnilimab AZURE Phase 2 trial initiated in alopecia areata following positive Phase 1 top-line data in single and multiple ascending dose healthy volunteer cohortsTop-line data from ongoing ANB032 healthy volunteer Phase 1 clinical trial anticipated in H1 2022JEMPERLI royalty monetization transaction completed with Sagard Healthcare Royalty Partners for $250 million upfront payment in exchange for capped return on royalties and certain milestones below $1 billion in annual salesEnded 2021 with approximately $615 million in cash and will continue to operate in a capital-efficient manner SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the fourth quarter and year ended December 31, 2021 and provided pipeline updates. “We advanced our wholly-owned antibody product pipeline and completed a $250 million royalty monetization transaction during 2021,” said Hamza Suria, president and chief executive officer of AnaptysBio. “We look forward to multiple clinical data readouts during 2022 and remain focused on developing first-in-class therapeutic antibodies using a capital-efficient business model.” Imsidolimab (Anti-IL-36 Receptor) Program Following an end-of-Phase 2 meeting with the FDA, we initiated our GEMINI-1 Phase 3 trial of imsidolimab in generalized pustular psoriasis (GPP) where the primary endpoint is the proportion of patients achieving a score of clear (0) or almost clear (1) skin on the Generalized Pustular Psoriasis Physician’s Global Assessment (GPPPGA) at week 4 in 45 patients randomized against placebo. These same patients will subsequently be enrolled into GEMINI-2, which will assess 6 months of monthly subcutaneous dosing and safety follow-up.We anticipate top-line data from the ACORN Phase 2 trial of imsidolimab in moderate-to-severe acne in H1 2022 and from...